Key result
New oral anticoagulants did not significantly reduce the risk of VTE or VTE-related death compared with control in patients with cancer (OR 0.80; 95% CI 0.39-1.65).
Why the study?
Do new oral anticoagulants (NOACs) reduce venous thromboembolism or VTE-related death in patients with cancer?
Meta-Analysis (n=1,197)
Do new oral anticoagulants (NOACs) reduce venous thromboembolism or VTE-related death in patients with cancer?
Odds Ratio: 0.8 (95% CI 0.39–1.65)
In patients with cancer, NOACs appear to have similar efficacy and safety compared to conventional anticoagulation or placebo, though cancer-specific trials are needed.
No takes yet. Share an insight, caveat, or question.
No demonstrated VTE benefit for NOACs in cancer; leaves open need for dedicated cancer-specific trials.
Sardar et al. (2014) conducted a meta-analysis in Cancer (n=1,197). New oral anticoagulants (NOACs) vs. Control (low-molecular-weight heparin/vitamin K antagonists/placebo) was evaluated on Venous thromboembolism (VTE) or VTE-related death (OR 0.80, 95% CI 0.39-1.65). New oral anticoagulants did not significantly reduce the risk of VTE or VTE-related death compared with control in patients with cancer (OR 0.80; 95% CI 0.39-1.65).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: